Daewoong Bio, a company specializing in brain health, is working to introduce blood-based Alzheimer’s disease diagnostic technology to Korea in collaboration with LabGenomics. This initiative aims to enhance the company's competitiveness in the central nervous system (CNS) business.


Daewoong Bio announced on June 15 that it hosted the “CNS Yeondu Symposium” at the Westin Josun Seoul on June 6 and 7, where it presented the latest treatment strategies for Alzheimer’s disease and introduced the blood-based Alzheimer’s diagnostic technology, Lumipulse, to leading scholars in Korea.

Daewoong Bio's 'Yeondu Symposium' where Jae-hak Ryu, CEO of LabGenomics, is introducing Lumipulse. Daewoong Bio

Daewoong Bio's 'Yeondu Symposium' where Jae-hak Ryu, CEO of LabGenomics, is introducing Lumipulse. Daewoong Bio

View original image

The core session of this symposium focused on blood-based biomarker testing, which is gaining attention in the field of Alzheimer’s diagnosis. Jaehak Ryu, CEO of LabGenomics and a speaker at the event, explained the features and clinical applicability of Lumipulse, a blood-based Alzheimer’s disease diagnostic test developed by Fujirebio.


The Lumipulse test is an in vitro diagnostic tool that assesses the likelihood of Alzheimer’s disease by measuring the ratio of specific tau protein (pTau217) and beta-amyloid (β-Amyloid 1-42) found in the blood. In May 2023, it received approval from the U.S. Food and Drug Administration (FDA). Compared to cerebrospinal fluid collection or positron emission tomography (PET), this diagnostic method is considered more accessible and cost-effective.


Tau protein and beta-amyloid are representative indicators that reveal changes in the brain during the progression of Alzheimer’s disease. Tau protein is involved in maintaining the structure of nerve cells, and abnormal changes may lead to neuronal damage. Beta-amyloid is known as a substance associated with the formation of amyloid plaques, a hallmark of Alzheimer’s disease.


Jaehak Ryu also introduced plans to operate an overseas referral testing service in partnership with QDx Pathology, a U.S. pathology diagnostic laboratory. This service allows domestic medical institutions to send patient specimens to specialized overseas testing facilities and receive diagnostic results. LabGenomics, in collaboration with Daewoong Bio, intends to expand the introduction of blood-based Alzheimer’s disease biomarker testing services that can be utilized by medical institutions in Korea.


Currently, Daewoong Bio is strengthening its position as a brain health specialist based on its CNS product lineup, which includes Gliatamin, Glyvixor, Beacept, Cerebrain, and Melaking. By collaborating with LabGenomics, the company plans to further bolster its competitiveness by bringing world-class blood-based Alzheimer’s disease diagnostic technology to the domestic market.


Jaehak Ryu, CEO of LabGenomics, stated, "As the use of blood-based biomarker testing is expanding in the field of Alzheimer’s diagnosis, it is important to share relevant information with healthcare professionals. Through this presentation, we aim to improve understanding of the Lumipulse test and overseas referral testing services, and provide information about diagnostic services available to domestic medical institutions."


Yoo Younggi, Head of Marketing at Daewoong Bio, said, "The environment for Alzheimer’s treatment is shifting, with growing emphasis not only on therapeutics but also on early diagnosis and patient-tailored management. Based on our CNS product lineup and innovative diagnostic technologies, Daewoong Bio will continue to offer healthcare professionals a wider range of options and treatment environments, and consistently strengthen our competitiveness as a brain health specialist."



Meanwhile, LabGenomics is a precision diagnostics company offering a variety of diagnostic solutions based on molecular diagnostic testing and genome analysis services. Recently, the company has expanded its global diagnostic service capabilities by partnering with U.S. pathology diagnostic laboratories, further enhancing its competitiveness in diagnostic testing services for both domestic and overseas medical institutions.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing